News | February 25, 2023
EMA recommends refusal of the marketing authorization for Lagevrio
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The partnership is announced at Aero India 2023, Bangalore
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Subscribe To Our Newsletter & Stay Updated
